title: Intestinal permeability to glucose after experimental traumatic brain injury: effect of gadopentetate dimeglumine administration.
abstract: Traumatic injuries are the leading cause of mortality in individuals aged 1-44 years, and brain injury significantly contributes to the outcome in nearly one half of all deaths from trauma. At the intestinal level, traumatic brain injury (TBI) induces profound effects, including gastrointestinal mucosa ischaemia and motility dysfunction. However, nothing is known concerning the effect of TBI on the intestinal absorption of glucose. Hence, the aim of this study was to investigate the effect of TBI on the intestinal absorption of glucose by investigating the effect of TBI on the jejunal mucosal-to-serosal apparent permeability (AP-to-BL P(app)) to two glucose model substrates, (3)H-2-deoxy-D-glucose ((3)H-DG) and (3)H-3-O-methyl-D-glucose ((3)H-OMG), and to (14)C-sorbitol. Additionally, we tested if gadopentetate dimeglumine administration could prevent any of the changes observed after TBI. Traumatic brain injury induced an increase in the AP-to-BL P(app) to (3)H-DG. After a 100-min. perfusion of the jejunum, the AP-to-BL P(app) to (3)H-DG in TBI rats was almost 70% higher than in the control rats. There was no change, however, in the AP-to-BL P(app) to neither (3)H-OMG nor (14)C-sorbitol. Interestingly enough, gadopentetate dimeglumine was able to prevent the increase in the AP-to-BL P(app) to (3)H-DG observed after TBI. Given the differences in transport characteristics between (3)H-DG and (3)H-OMG, our results point to the possibility of the Na(+)-independent glucose transporter 2 (GLUT2) being activated by TBI (as the P(app) to (3)H-DG, a GLUT2 substrate, was increased) and the Na(+)-dependent glucose co-transporter (SGLT1) being inhibited by TBI (as the P(app) to (3)H-OMG, a GLUT2 and SGLT1 substrate, remained unchanged). Moreover, gadopentetate dimeglumine prevented these changes associated with TBI.
authors.affiliation: Department of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto, Porto, Portugal.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Santos
authors.forename: Pedro
authors.initials: P
authors.lastname: Gonçalves
authors.forename: João R
authors.initials: JR
authors.lastname: Araújo
authors.forename: Fátima
authors.initials: F
authors.lastname: Martel
mesh_terms: D019325:3-O-Methylglucose / Q000378:metabolism; D000818:Animals; D001692:Biological Transport; D001930:Brain Injuries / Q000378:metabolism*; D003847:Deoxyglucose / Q000378:metabolism; D019786:Gadolinium DTPA / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism*; D051273:Glucose Transporter Type 2 / Q000819:agonists; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D007408:Intestinal Absorption / Q000502:physiology*; D007413:Intestinal Mucosa / Q000378:metabolism*; D007583:Jejunum / Q000378:metabolism; D008297:Male; D010539:Permeability; D051381:Rats; D017208:Rats, Wistar; D051269:Sodium-Glucose Transporter 1 / Q000037:antagonists & inhibitors; D013012:Sorbitol / Q000378:metabolism
chemical_list: D051273:Glucose Transporter Type 2; C495683:Slc2a2 protein, rat; C495676:Slc5a1 protein, rat; D051269:Sodium-Glucose Transporter 1; D019325:3-O-Methylglucose; D013012:Sorbitol; D003847:Deoxyglucose; D005947:Glucose; D019786:Gadolinium DTPA